glp 1 dementia prevention GLP-1 mimetics and cognition Glucagon-like peptide-1 receptor agonists for

The prasinezumab trial (PASADENA), however, showed significantly slower decline in MDS-UPDRS part III scores (a key secondary endpoint) at week 52 as well as consistent results in exploratory digital motor measures [207]

Thats a bet that will only pay off if they can significantly expand its output

Ideal for athletes seeking to improve stamina and performance

Autism is one of the five pervasive developmental disorders (PDD), which are characterized by widespread abnormalities of social interactions and communication, severely restricted interests and highly repetitive behavior

Targeting the IGF1R/PI3K/AKT pathway sensitizes Ewing sarcoma to BET bromodomain inhibitors

Metabolic syndrome and related disorders